Fexofenadine hydrochloride topical - OrchestratePharma
Alternative Names: OP-2101Latest Information Update: 28 May 2025
At a glance
- Originator Cellix Bio
- Developer Cellix Bio; OrchestratePharma
- Class Acetic acids; Anti-inflammatories; Antiallergics; Benzhydryl compounds; Nonsedating antihistamines; Piperidines; Skin disorder therapies; Small molecules
- Mechanism of Action Histamine H1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Skin disorders
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Skin-disorders(In volunteers) in Bangladesh (Topical, Lotion)
- 16 Oct 2022 OrchestratePharma completes a phase-I trial in Skin disorders (In volunteers) in Bangladesh (Topical) (NCT05461456)
- 15 Aug 2022 OrhestratePharma has patent protection for hydrochloride composition of matter PCT application worldwide(OrhestratePharma website).